Table 2.
Characteristics, treatment, and survivals in 24 patients according to endocrine responsiveness.
| No | Agea | Family history | Initial Stage | ER | Adjuvant endocrine therapy | DFS | First site of metastatic disease | Ageb | Site of sample | Platform | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary endocrine resistance | |||||||||||
| 1 | 42 | Other | II | 100 | None | 1 | Lymph node, bone | 44 | Primary | CLHURC | 33 |
| 2 | 33 | Breast/ovary | III | 5 | None | 2 | Lymph node, lung, liver, spleen | 33 | Primary | OncoPrime | 12 |
| 3 | 67 | Other | II | 80 | AI | 3 | Chest wall | 70 | Primary | CLHURC | 42 |
| 4 | 41 | Breast/ovary | II | 90 | TAM, OFS | 16 | Lung | 44 | Primary | CLHURC | 57 |
| 5 | 48 | Other | − | − | TAM | 7 | Lymph node | 67 | Metastasis (ovary) | CLHURC | > 269 |
| 6 | 42 | Breast/ovary | II | 95 | TAM | 11 | Bone | 45 | Metastasis (chest wall) | OncoPrime | 46 |
| 7 | 61 | None | II | 100 | AI | 23 | Liver, bone | 66 | Metastasis (liver) | CLHURC | 71 |
| Secondary endocrine resistance | |||||||||||
| 8 | 61 | Other | II | > 65 | AI | 36 | − | 65 | Primary | CLHURC | − |
| 9 | 58 | Breast/ovary | III | 100 | TAM | 54 | Chest wall | 72 | Primary | CLHURC | 187 |
| 10 | 63 | Breast/ovary | II | − | TAM → AI | 60 | Chest wall | 68 | Primary | CLHURC | 78 |
| 11 | 32 | Breast/ovary | IV | > 65 | N/A | N/A | Bone | 33 | Primary | CLHURC | 20 |
| 12 | 66 | None | IV | 100 | N/A | N/A | Lymph node, pleura | 70 | Primary | CLHURC | 71 |
| 13 | 43 | Breast/ovary | III | 100 | TAM | 56 | Lymph node | 50 | Metastasis (lymph node) | CLHURC | 107 |
| 14 | 51 | Other | II | − | TAM → AI | 58 | Lymph node | 64 | Metastasis (lung) | CLHURC | > 188 |
| 15 | 28 | Breast/ovary | II | > 65 | TAM | 65 | Lymph node, bone | 38 | Metastasis (liver) | CLHURC | 114 |
| Endocrine-responsive breast cancer | |||||||||||
| 16 | 61 | Breast/ovary | I | > 65 | TAM | 97 | Lymph node, bone | 70 | Primary | CLHURC | > 159 |
| 17 | 46 | Other | III | 60 | AI | 128 | − | 57 | Primary | CLHURC | − |
| 18 | 39 | None | IV | > 65 | N/A | N/A | Bone | 46 | Primary | CLHURC | 126 |
| 19 | 72 | Other | IV | 90 | N/A | N/A | Lymph node, bone, pleura | 72 | Primary (ILC) | CLHURC | > 49 |
| 20 | 57 | None | III | 100 | AI → TAM | 74 | − | 66 | Metastasis (bone) | CLHURC | − |
| 21 | 58 | None | III | − | AI | 77 | − | 68 | Metastasis (liver) | CLHURC | − |
| 22 | 39 | Breast/ovary | − | − | TAM | 124 | Lung | 59 | Metastasis (lung) | CLHURC | > 204 |
| 23 | 59 | Other | II | 100 | TAM → AI | 148 | Brain | 73 | Metastasis (brain) | CLHURC | > 205 |
| 24 | 39 | None | II | 95 | TAM | 247 | Lymph node | 66 | Metastasis (lymph node) | CLHURC | 361 |
ER estrogen receptor (% of positive cells), DFS disease-free survival (months), OS overall survival (months), AI aromatase inhibitor, TAM tamoxifen, OFS ovarian function suppression, ILC invasive lobular carcinoma, N/A not applicable, − unknown.
aAge at the time of initial diagnosis (years).
bAge at the time of clinical sequencing (years).